Background/Aim: Metastatic anaplastic thyroid cancer is associated with a dismal prognosis. We evaluated outcome and prognostic factors in patients receiving radiation to the primary tumor in metastatic anaplastic thyroid cancer (ATC). Patients and Methods: All consecutive patients with metastatic ATC (n=20) undergoing irradiation between 2009 and 2019 for anaplastic thyroid cancer were investigated. Results: Median survival time and median progression-free survival were 2 (range=1-22) and 2 (1-20) months. In univariate analyses, surgery, concurrent or sequential chemotherapy and higher radiation dose escalation (>39 Gy) were correlated with longer overall survival (p=0.005, p=0.018 and p=0.038), respectively. Karnofsky performance status >70% showed a trend of longer survival time (p=0.062). Limited metastatic disease, surgery and concurrent/sequential chemotherapy are correlated with longer progression-free survival times (p=0.043, p=0.024 and p=0.039), respectively. Conclusion: Radiation to the primary tumor in metastatic anaplastic thyroid cancer is safe and offers durable local control. Treatment intensification including concurrent or sequential chemotherapy and radiation dose escalation were associated with longer survival rates and should be considered in selected patients with metastatic disease.

中文翻译：

---

转移性甲状腺未分化癌原发肿瘤的放射治疗

背景/目的：转移性未分化甲状腺癌与预后不良有关。我们评估了转移性未分化甲状腺癌 (ATC) 原发肿瘤患者接受放射治疗的结果和预后因素。患者和方法：研究了 2009 年至 2019 年间因未分化甲状腺癌接受放射治疗的所有连续转移性 ATC 患者（n=20）。结果：中位生存时间和中位无进展生存期分别为 2 (范围 = 1-22) 和 2 (1-20) 个月。在单变量分析中，手术、同步或序贯化疗和更高的放射剂量递增 (>39 Gy) 分别与更长的总生存期相关 (p=0.005、p=0.018 和 p=0.038)。Karnofsky 体能状态 >70% 显示出生存时间更长的趋势 (p=0.062)。局限性转移性疾病，手术和同步/序贯化疗与更长的无进展生存时间相关（分别为 p=0.043、p=0.024 和 p=0.039）。结论：对转移性未分化甲状腺癌原发肿瘤进行放射治疗是安全的，并提供持久的局部控制。包括同步或序贯化疗和放疗剂量递增在内的强化治疗与更长的生存率相关，应在选定的转移性疾病患者中考虑。